[1] Deo SV, Bhutani M, Shukla NK, et al. Randomized trial comparing neo-adjuvant versus adjuvant chemotherapy in operable locally advanced breast cancer (T4b N0-2 M0)[J]. J Surg Oncol, 2003, 84(4): 192-7. [2] Ganem G, Tubiana-Hulin M, Fumoleau P, et al. Phase Ⅱ trial combining docetaxel and doxorubicin as neoadjuvant chemotherapy in patients with operable breast cancer[J]. Ann Oncol, 2003, 14(11):1623-8. [3] Lee SH, Chung MA, Quddus MR. The effect of neoadjuvant chemotherapy on estrogen and progesterone receptor expression and hormonal receptor status in breast cancer[J]. Am J Surg, 2003, 186(4): 384-50. [4] 沈镇宙,邵志敏.现代乳腺肿瘤学进展[M].上海科学技术文献出版社,2002.87-91. [5] Lo SS, Wang HC, Shyr YM. Can the hormonal receptor status of primary breast cancer be altered by neoadjuvant chemotherapy [J]?J Surg Oncol, 1994, 57(2): 94-6. [6] Jain V, Landry M, Levine EA. The stability of estrogen and progesterone receptors in patients receiving preoperative chemotherapy for locally advanced breast carcinoma [J]. Am Surg, 1996, 62(2):162-5. [7] Makris A, Powels TJ, Allred DC, et al. Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer: a pilot study[J]. Breast Cancer Res Treat, 1999, 53(1): 51-9. [8] Lee SH, Chung MA, Quddus MR. The effect of neoadjuvant chemotherapy on estrogen and progesterone receptor expression and hormonal receptor status in breast cancer[J]. Am J Surg, 2003, 186(4): 384-50. [9] 张震寰,吴凯南,汪康莹,等.术前化疗对晚期乳腺癌雌激素受体含量的影响[J].中国肿瘤临床,2001,28(12):895-7Zhang ZH, Wu KN, Wang KY, et al. Effect of pre-operative chemotherapy on estrogen receptor content in advanced breast cancer[J]. Chin J Clin Oncol, 2001, 28(12): 895-7. [10] Taucher S, Rudas M, Mader RM, et al. Influence of neoadjuvant therapy with epirubicin and docetaxel on the expression of HER2/neu in patients with breast cancer [J]. Breast Cancer Res Treat, 2003, 82(3): 207-13. |